BR112023024627A2 - Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas - Google Patents
Proteínas renais de fusão ativas e métodos de tratamento usando as mesmasInfo
- Publication number
- BR112023024627A2 BR112023024627A2 BR112023024627A BR112023024627A BR112023024627A2 BR 112023024627 A2 BR112023024627 A2 BR 112023024627A2 BR 112023024627 A BR112023024627 A BR 112023024627A BR 112023024627 A BR112023024627 A BR 112023024627A BR 112023024627 A2 BR112023024627 A2 BR 112023024627A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- treatment methods
- domains
- active kidney
- factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192835P | 2021-05-25 | 2021-05-25 | |
| PCT/US2022/030658 WO2022251168A1 (en) | 2021-05-25 | 2022-05-24 | Kidney active fusion proteins and methods of treatment using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024627A2 true BR112023024627A2 (pt) | 2024-02-20 |
Family
ID=84230212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024627A BR112023024627A2 (pt) | 2021-05-25 | 2022-05-24 | Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240262877A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347666A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7905369B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240013770A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117396519A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022283254A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024627A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177162A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308754A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014037A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022251168A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116472065A (zh) * | 2020-10-05 | 2023-07-21 | 阿雷克森制药公司 | 治疗皮肌炎的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003527115A (ja) | 2000-03-13 | 2003-09-16 | セント ビンセンツ ホスピタル | 新規のh因子関連タンパク質5及びその抗体 |
| JP5250548B2 (ja) * | 2006-06-21 | 2013-07-31 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 疾患の治療のための補体h因子の標的化 |
| AU2011222883B2 (en) | 2010-03-05 | 2016-05-26 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
| EP3033093A1 (en) * | 2013-08-16 | 2016-06-22 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| WO2018075462A1 (en) | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating and preventing transplant-associated injury |
| WO2020041644A1 (en) * | 2018-08-22 | 2020-02-27 | Alexion Pharmaceuticals, Inc. | Fusion proteins and methods of treating complement dysregulation using the same |
-
2022
- 2022-05-24 AU AU2022283254A patent/AU2022283254A1/en active Pending
- 2022-05-24 WO PCT/US2022/030658 patent/WO2022251168A1/en not_active Ceased
- 2022-05-24 IL IL308754A patent/IL308754A/en unknown
- 2022-05-24 EP EP22811954.1A patent/EP4347666A4/en active Pending
- 2022-05-24 BR BR112023024627A patent/BR112023024627A2/pt unknown
- 2022-05-24 MX MX2023014037A patent/MX2023014037A/es unknown
- 2022-05-24 JP JP2023572788A patent/JP7905369B2/ja active Active
- 2022-05-24 KR KR1020237044189A patent/KR20240013770A/ko active Pending
- 2022-05-24 CN CN202280035932.2A patent/CN117396519A/zh active Pending
- 2022-05-24 CA CA3177162A patent/CA3177162A1/en active Pending
- 2022-05-24 US US18/561,469 patent/US20240262877A1/en active Pending
-
2025
- 2025-05-26 JP JP2025086967A patent/JP2025116068A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023014037A (es) | 2024-01-15 |
| EP4347666A1 (en) | 2024-04-10 |
| CN117396519A (zh) | 2024-01-12 |
| WO2022251168A9 (en) | 2023-02-16 |
| CA3177162A1 (en) | 2022-11-25 |
| JP2024520421A (ja) | 2024-05-24 |
| JP2025116068A (ja) | 2025-08-07 |
| KR20240013770A (ko) | 2024-01-30 |
| AU2022283254A9 (en) | 2023-12-07 |
| AU2022283254A1 (en) | 2023-11-30 |
| US20240262877A1 (en) | 2024-08-08 |
| WO2022251168A1 (en) | 2022-12-01 |
| JP7905369B2 (ja) | 2026-08-14 |
| IL308754A (en) | 2024-01-01 |
| EP4347666A4 (en) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121931T1 (el) | Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης | |
| DE60135498D1 (de) | Produktion von ganzen Antikörpern in prokaryontischen Zellen | |
| ATE476654T1 (de) | Plattform für protein-profiling | |
| DE60005953D1 (de) | Stapelbare statische mischelemente | |
| DE60138715D1 (de) | Tnf-rezeptor-ähnliche moleküle und deren anwendungen | |
| BRPI0410876A (pt) | molécula inibidora do complemento, anticorpo, proteìna de fusão, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar uma molécula inibidora do complemento ou um seu equivalente funcional ou uma proteìna de fusão, para identificar um ligando de uma molécula inibidora do complemento, ou um seu equivalente funcional, para tratar um animal que esteja sofrendo de uma doença ou um distúrbio mediados pelo complemento, ou prevenir que um aninal desenvolva uma doença ou um disturbio mediados pelo complemento, para vacinar um animal contra uma doença ou um distúrbio transmitidos por um artrópode hematófago e para inibir as vias do complemento clássica e alternativa em uma célula, tecido ou organismo não humano, composição, uso de uma molécula inibidora do complemento, uma proteìna de fusão ou uma molécula de ácido nucleico | |
| EP1322307A4 (en) | METHOD FOR THE TREATMENT OF CELL PROLIFERATION TROUBLES AND VIRUS INFECTIONS | |
| UY28170A1 (es) | Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes. | |
| Lai et al. | Matriptase complexes and prostasin complexes with HAI-1 and HAI-2 in human milk: significant proteolysis in lactation | |
| de Roodt et al. | Cross-reactivity and heterologous neutralization of crotaline antivenoms used in Argentina | |
| SE8902532D0 (sv) | Bestaemning av plasmaproteiner | |
| BR0313033A (pt) | anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica | |
| DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
| ATE384263T1 (de) | Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen | |
| BR0113099A (pt) | Gene e proteìna relacionados com esquizofrenia | |
| DE69913325D1 (de) | Nephrin gen und protein | |
| ATE466870T1 (de) | Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems | |
| ATE368687T1 (de) | Thrombopoietinproteine mit verbesserten eigenschaften | |
| MX2023014037A (es) | Proteinas de fusion activas renales y metodos de tratamiento que usan las mismas. | |
| EP1549672A4 (en) | ABLATED SLAM DEPENDENT ENTRY | |
| ATE349702T1 (de) | Nachweis und quantifizierung von cripto-1 | |
| CO2023015999A2 (es) | Proteínas de fusión activas renales y métodos de tratamiento que usan las mismas | |
| ATE414776T1 (de) | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten | |
| ATE545421T1 (de) | Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat | |
| Gilbert et al. | Purification of fibrinogen and virus removal using preparative electrophoresis |